Synthetic Biology: Science, Policy, and Ethics
Synthetic biology, "which aims to apply standardized engineering techniques to biology and thereby create organisms or biological systems with novel or specialized functions to address countless needs,”* offers the potential for tremendous benefit, alongside a range of possible risks. How should these benefits and risks be balanced, from a scientific, ethical, and policy perspective? This panel engaged a leader in the field of synthetic biology and an expert in risk regulation and policy in discussion of these issues.
Adam Finkel, Senior Fellow and Executive Director, Penn Program on Regulation, University of Pennsylvania Law School and Clinical Professor of Environmental Health Sciences, University of Michigan School of Public Health
Moderator: Holly Fernandez Lynch, Executive Director, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School
Couldn't attend the event? Check out some of our presenters' slide presentations!
George Church, "Biology, Policy, & Ethics"
This event was free and open to the public.
Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
VIDEO: Holly Fernandez Lynch, Introduction
VIDEO: George Church, "Biology, Policy, & Ethics"
VIDEO: Adam Finkel, "Two Complementary 'Solution-Focused' Approaches to Maximizing Net Societal Benefit from Synthetic Biology"
VIDEO: George Church, response
VIDEO: Audience Q & A